Citations

Clear

1053 citation(s) found for "Andre, F".

Association Between Disease-Free Survival and Overall Survival When Survival Is Prolonged After Recurrence in Patients Receiving Cytotoxic Adjuvant Therapy for Colon Cancer: Simulations Based on the 20,800 Patient ACCENT Data Set
Gramont, Aimery de , Shi, Qian , Benedetti, Jacqueline, Bot, Brian M. , O’Callaghan, Chris J. , Yothers, Greg , Goldberg, Richard M. , Blanke, Charles D. , Benson, Al B. , Deng, Qiqi , André, Thierry , Sargent, Daniel J. , Hubbard, Joleen M. , O’Connell, Michael J. , Buyse, Marc , Alberts, Steven R. , Wolmark, Norman , Grothey, Axel , Sargent, Daniel J , André, Thierry , Shi, Qian , Yothers, Greg

Mayo Clinic

Journal of Clinical Oncology | December 15, 2009 | Volume: 28 | Issue: 3 | Pages: 460-465

10.1200/jco.2009.23.1407 | PMID 20008641 Get It

Purpose We previously validated disease-free survival (DFS) as a surrogate for overall survival (OS) in fluorouracil-based adjuvant colon cancer clinical trials. New therapies have extended survival after recurrence from 1 to approximately 2 years. We examined the possible impact of this improvement on the DFS/OS association. Methods The Adjuvant Colon Cancer Endpoints (ACCENT) data set of 20,898 patients was analyzed. In an exploratory fashion, time from recurrence to death in patients experiencing recurrence was extended using several algorithms, and the association of DFS after 3 years of median follow-up and OS after varying lengths of follow-up (median of 5, 6, and 7 years) was assessed. Results Seven thousand four hundred two patients (35%) experienced recurrence. Median time from recurrence to death was 24 months in the hypothetical data sets. When times from recurrence to death were doubled, the association between treatment effects on DFS and 5-year OS was modest (R2 = 0.51 for both 2- and 3-year DFS) but remained strong for DFS and 6-year OS (R2 = 0.67 for both 2- and 3-year DFS) and 7-year OS (R2 = 0.70 for both 2- and 3-year DFS). The reduced DFS/OS association with extended survival after recurrence was greater in stage II than stage III patients. Multiple simulations provided consistent findings. Conclusion Extended survival after recurrence reduces the association between treatment effects on 3-year DFS and 5-year OS, particularly in stage II patients; longer follow-up strengthens the association. In modern adjuvant trials, 6 or 7 years may be required to demonstrate OS improvements, further supporting DFS as the preferred primary end point for future adjuvant colon cancer clinical trials.
Ethical Issues in Cardiovascular Research Involving Humans
Frye, Robert L. , Simari, Robert D., Brumm, Shari K., Myerle, Kathleen, Jaffe, Allan S. , Holmes, David R. , Gersh, Bernard J. , Burnett, John , Jaffe, Allan S. , Lerman, Amir , Terzic, André

Mayo Clinic

Circulation | November 23, 2009 | Volume: 120 | Issue: 21 | Pages: 2113-2121

10.1161/circulationaha.107.752766 | PMID 19933950 Get It

iPS Programmed Without c-MYC Yield Proficient Cardiogenesis for Functional Heart Chimerism
Martinez‐Fernandez, Almudena , Nelson, Timothy J. , Reyes, Santiago , Alekseev, Alexey E., Pérez-Terzic, Carmen, Yamada, Satsuki , Ikeda, Yasuhiro , Terzic, André , Nelson, Timothy J

Mayo Clinic

Circulation Research | August 21, 2009 | Volume: 105 | Issue: 7 | Pages: 648-656

10.1161/circresaha.109.203109 | PMID 19696409 Get It

Rationale : Induced pluripotent stem cells (iPS) allow derivation of pluripotent progenitors from somatic sources. Originally, iPS were induced by a stemness-related gene set that included the c-MYC oncogene. Objective : Here, we determined from embryo to adult the cardiogenic proficiency of iPS programmed without c-MYC, a cardiogenicity-associated transcription factor. Methods and Results : Transgenic expression of 3 human stemness factors SOX2, OCT4, and KLF4 here reset murine fibroblasts to the pluripotent ground state. Transduction without c-MYC reversed cellular ultrastructure into a primitive archetype and induced stem cell markers generating 3-germ layers, all qualifiers of acquired pluripotency. Three-factor induced iPS (3F-iPS) clones reproducibly demonstrated cardiac differentiation properties characterized by vigorous beating activity of embryoid bodies and robust expression of cardiac Mef2c, α-actinin, connexin43, MLC2a, and troponin I. In vitro isolated iPS-derived cardiomyocytes demonstrated functional excitation-contraction coupling. Chimerism with 3F-iPS derived by morula-stage diploid aggregation was sustained during prenatal heart organogenesis and contributed in vivo to normal cardiac structure and overall performance in adult tumor-free offspring. Conclusions : Thus, 3F-iPS bioengineered without c-MYC achieve highest stringency criteria for bona fide cardiogenesis enabling reprogrammed fibroblasts to yield de novo heart tissue compatible with native counterpart throughout embryological development and into adulthood.
ATP-Sensitive K+ Channel Knockout Induces Cardiac Proteome Remodeling Predictive of Heart Disease Susceptibility
Arrell, D. Kent , Zlatković, Jelena, Kane, Garvan C. , Yamada, Satsuki , Terzic, André

Mayo Clinic

Journal of Proteome Research | August 12, 2009 | Volume: 8 | Issue: 10 | Pages: 4823-4834

10.1021/pr900561g | PMID 19673485 Get It

Repair of Acute Myocardial Infarction by Human Stemness Factors Induced Pluripotent Stem Cells
Nelson, Timothy J. , Martinez‐Fernandez, Almudena , Pérez-Terzic, Carmen, Yamada, Satsuki , Ikeda, Yasuhiro , Terzic, André , Nelson, Timothy J

Mayo Clinic

Circulation | July 21, 2009 | Volume: 120 | Issue: 5 | Pages: 408-416

10.1161/circulationaha.109.865154 | PMID 19620500 Get It

Background— Nuclear reprogramming provides an emerging strategy to produce embryo-independent pluripotent stem cells from somatic tissue. Induced pluripotent stem cells (iPS) demonstrate aptitude for de novo cardiac differentiation, yet their potential for heart disease therapy has not been tested. Methods and Results— In this study, fibroblasts transduced with human stemness factors OCT3/4, SOX2, KLF4, and c-MYC converted into an embryonic stem cell–like phenotype and demonstrated the ability to spontaneously assimilate into preimplantation host morula via diploid aggregation, unique to bona fide pluripotent cells. In utero, iPS-derived chimera executed differentiation programs to construct normal heart parenchyma patterning. Within infarcted hearts in the adult, intramyocardial delivery of iPS yielded progeny that properly engrafted without disrupting cytoarchitecture in immunocompetent recipients. In contrast to parental nonreparative fibroblasts, iPS treatment restored postischemic contractile performance, ventricular wall thickness, and electric stability while achieving in situ regeneration of cardiac, smooth muscle, and endothelial tissue. Conclusions— Fibroblasts reprogrammed by human stemness factors thus acquire the potential to repair acute myocardial infarction, establishing iPS in the treatment of heart disease.
Evidence for a Role of NTS2 Receptors in the Modulation of Tonic Pain Sensitivity
Roussy, Geneviève, Dansereau, Marc‐André, Baudisson, Stéphanie, Ezzoubaa, Faouzi, Belleville, Karine, Beaudet, Nicolas , Martínez, Jean , Richelson, Elliott, Sarret, Philippe

Mayo Clinic

Molecular Pain | July 7, 2009 | Volume: 5 | Issue: No issue available | Pages: No page available

10.1186/1744-8069-5-38 | PMID 19580660 Get It

BackgroundCentral neurotensin (NT) administration results in a naloxone-insensitive antinociceptive response in animal models of acute and persistent pain. Both NTS1 and NTS2 receptors were shown to be required for different aspects of NT-induced analgesia. We recently demonstrated that NTS2 receptors were extensively associated with ascending nociceptive pathways, both at the level of the dorsal root ganglia and of the spinal dorsal horn. Then, we found that spinally administered NTS2-selective agonists induced dose-dependent antinociceptive responses in the acute tail-flick test. In the present study, we therefore investigated whether activation of spinal NTS2 receptors suppressed the persistent inflammatory pain symptoms observed after intraplantar injection of formalin.ResultsWe first demonstrated that spinally administered NT and NT69L agonists, which bind to both NTS1 and NTS2 receptors, significantly reduced pain-evoked responses during the inflammatory phase of the formalin test. Accordingly, pretreatment with the NTS2-selective analogs JMV-431 and levocabastine was effective in inhibiting the aversive behaviors induced by formalin. With resolution at the single-cell level, we also found that activation of spinal NTS2 receptors reduced formalin-induced c-fos expression in dorsal horn neurons. However, our results also suggest that NTS2-selective agonists and NTS1/NTS2 mixed compounds differently modulated the early (21–39 min) and late (40–60 min) tonic phase 2 and recruited endogenous pain inhibitory mechanisms integrated at different levels of the central nervous system. Indeed, while non-selective drugs suppressed pain-related behaviors activity in both part of phase 2, intrathecal injection of NTS2-selective agonists was only efficient in reducing pain during the late phase 2. Furthermore, assessment of the stereotypic pain behaviors of lifting, shaking, licking and biting to formalin also revealed that unlike non-discriminative NTS1/NTS2 analogs reversing all nociceptive endpoint behaviors, pure NTS2 agonists specifically inhibited paw lifting, supporting a role of NTS2 in spinal modulation of persistent nociception.ConclusionThe present study provides the first demonstration that activation of NTS2 receptors produces analgesia in the persistent inflammatory pain model of formalin. The dichotomy between these two classes of compounds also indicates that both NTS1 and NTS2 receptors are involved in tonic pain inhibition and implies that these two NT receptors modulate the pain-induced behavioral responses by acting on distinct spinal and/or supraspinal neural circuits. In conclusion, development of NT agonists targeting both NTS1 and NTS2 receptors could be useful for chronic pain management.
Stem Cell Transplant into Preimplantation Embryo Yields Myocardial Infarction-Resistant Adult Phenotype
Nelson, Timothy J. , Behfar, Atta , Crespo‐Diaz, Ruben , Fraidenraich, Diego , Yamada, Satsuki , Terzic, André , Behfar, Atta , Nelson, Timothy J

Mayo Clinic

Stem Cells | May 14, 2009 | Volume: 27 | Issue: 7 | Pages: 1697-1705

10.1002/stem.116 | PMID 19544428 Get It

Abstract Stem cells are an emerging strategy for treatment of myocardial infarction, limited however to postinjury intervention. Preventive stem cell-based therapy to augment stress tolerance has yet to be considered for lifelong protection. Here, pluripotent stem cells were microsurgically introduced at the blastocyst stage of murine embryo development to ensure stochastic integration and sustained organ contribution. Engineered chimera displayed excess in body weight due to increased fat deposits, but were otherwise devoid of obesity-related morbidity. Remarkably, and in sharp contrast to susceptible nonchimeric offspring, chimera was resistant to myocardial infarction induced by permanent coronary occlusion. Infarcted nonchimeric adult hearts demonstrated progressive deterioration in ejection fraction, while age-matched 12–14-months-old chimera recovered from equivalent ischemic insult to regain within one-month preocclusion contractile performance. Electrical remodeling and ventricular enlargement with fibrosis, prominent in failing nonchimera, were averted in the chimeric cohort characterized by an increased stem cell load in adipose tissue and upregulated markers of biogenesis Ki67, c-Kit, and stem cell antigen-1 in the myocardium. Favorable outcome in infarcted chimera translated into an overall benefit in workload capacity and survival. Thus, prenatal stem cell transplant yields a cardioprotective phenotype in adulthood, expanding cell-based indications beyond traditional postinjury applications to include pre-emptive therapy. Disclosure of potential conflicts of interest is found at the end of this article.
Induced Pluripotent Stem Cells: Reprogrammed without a Trace
Nelson, Timothy J. , Terzic, André , Nelson, Timothy J

Mayo Clinic

Regenerative Medicine | May 13, 2009 | Volume: 4 | Issue: 3 | Pages: 333-335

10.2217/rme.09.16 | PMID 19438303 Get It

Adenylate Kinase and AMP Signaling Networks: Metabolic Monitoring, Signal Communication and Body Energy Sensing
Dzeja, Petras P. , Terzic, André

Mayo Clinic

International Journal of Molecular Sciences | April 17, 2009 | Volume: 10 | Issue: 4 | Pages: 1729-1772

10.3390/ijms10041729 | PMID 19468337 Get It

Adenylate kinase and downstream AMP signaling is an integrated metabolic monitoring system which reads the cellular energy state in order to tune and report signals to metabolic sensors. A network of adenylate kinase isoforms (AK1-AK7) are distributed throughout intracellular compartments, interstitial space and body fluids to regulate energetic and metabolic signaling circuits, securing efficient cell energy economy, signal communication and stress response. The dynamics of adenylate kinase-catalyzed phosphotransfer regulates multiple intracellular and extracellular energy-dependent and nucleotide signaling processes, including excitation-contraction coupling, hormone secretion, cell and ciliary motility, nuclear transport, energetics of cell cycle, DNA synthesis and repair, and developmental programming. Metabolomic analyses indicate that cellular, interstitial and blood AMP levels are potential metabolic signals associated with vital functions including body energy sensing, sleep, hibernation and food intake. Either low or excess AMP signaling has been linked to human disease such as diabetes, obesity and hypertrophic cardiomyopathy. Recent studies indicate that derangements in adenylate kinase-mediated energetic signaling due to mutations in AK1, AK2 or AK7 isoforms are associated with hemolytic anemia, reticular dysgenesis and ciliary dyskinesia. Moreover, hormonal, food and antidiabetic drug actions are frequently coupled to alterations of cellular AMP levels and associated signaling. Thus, by monitoring energy state and generating and distributing AMP metabolic signals adenylate kinase represents a unique hub within the cellular homeostatic network.
The Osteogenic Transcription Factor Runx2 Controls Genes Involved in Sterol/Steroid Metabolism, Including Cyp11a1 in Osteoblasts
Teplyuk, Nadiya M., Lou, Yang , Hawse, John R. , Hassan, Mohammad Q., Teplyuk, Viktor I., Pratap, Jitesh , Galindo, Mario , Stein, Janet L. , Stein, Gary S., Lian, Jane B. , Wijnen, André J. van , Zhang, Ying , van Wijnen, Andre J

Mayo Clinic

Molecular Endocrinology | April 3, 2009 | Volume: 23 | Issue: 6 | Pages: 849-861

10.1210/me.2008-0270 | PMID 19342447 Get It